• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Liminal BioSciences Inc. (Amendment)

    9/27/23 4:05:14 PM ET
    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LMNL alert in real time by email
    SC 13D/A 1 tm2326986d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    SCHEDULE 13D/A

    (Amendment No. 4)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    Liminal BioSciences Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    53272L202

    (CUSIP Number)

     

    Eugene Siklos, President

    c/o Thomvest Asset Management Ltd.
    65 Queen Street West, Suite 2400
    Toronto, Ontario, M5H 2M8

    (416) 364-8700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    September 27, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act.

     

     

     

     

     

    CUSIP No. 53272L202

     

    1 NAMES OF REPORTING PERSONS  
      Structured Alpha LP  
         
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨
        (b) ¨
         
    3 SEC USE ONLY  
         
    4 SOURCE OF FUNDS (SEE INSTRUCTIONS)  
      WC   
         
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) ¨
         
    6 CITIZENSHIP OR PLACE OF ORGANIZATION  
      Cayman Islands  

     

      7 SOLE VOTING POWER
        3,249,534
         
    NUMBER OF SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH
    8 SHARED VOTING POWER
      0
       
    9 SOLE DISPOSITIVE POWER
        3,249,534
         
      10 SHARED DISPOSITIVE POWER
        0

     

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
      3,249,534  
         
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
         
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
      100%(1)  
         
    14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
      PN  

     

     

    (1) This percentage is calculated based upon 3,249,534 outstanding common shares, no par value per share (“Common Shares”) of Liminal BioSciences Inc. (the “Issuer”) as of August 15, 2023 as reported in the Issuer’s Proxy Circular, which is attached as Exhibit (a)(2)(i) to the Schedule 13E-3 filed with the Securities and Exchange Commission (the “SEC”) on August 17, 2023.

     

    2

     

     

    CUSIP No. 53272L202

     

    1 NAMES OF REPORTING PERSONS  
      Thomvest Asset Management Ltd.  
         
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨
        (b) ¨
         
    3 SEC USE ONLY  
         
    4 SOURCE OF FUNDS (SEE INSTRUCTIONS)  
      OO  
         
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) ¨
         
    6 CITIZENSHIP OR PLACE OF ORGANIZATION  
      Ontario, Canada  

     

      7 SOLE VOTING POWER
        0
         
    NUMBER OF SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH
    8 SHARED VOTING POWER
      3,249,534
       
    9 SOLE DISPOSITIVE POWER
        0
         
      10 SHARED DISPOSITIVE POWER
        3,249,534

     

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
      3,249,534  
         
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
         
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
      100%(1)  
         
    14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
      CO  

     

     

    (1) This percentage is calculated based upon 3,249,534 outstanding Common Shares of the Issuer as of August 15, 2023 as reported in the Issuer’s Proxy Circular which is attached as Exhibit (a)(2)(i) to the Schedule 13E-3 filed with the SEC on August 17, 2023.

     

    3

     

     

    CUSIP No. 53272L202

     

    1 NAMES OF REPORTING PERSONS  
      Peter J. Thomson(1)  
         
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨
        (b) ¨
         
    3 SEC USE ONLY  
         
    4 SOURCE OF FUNDS (SEE INSTRUCTIONS)  
      OO  
         
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) ¨
         
    6 CITIZENSHIP OR PLACE OF ORGANIZATION  
      Canada  

     

      7 SOLE VOTING POWER
        0
         
    NUMBER OF SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH
    8 SHARED VOTING POWER
      3,249,534
       
    9 SOLE DISPOSITIVE POWER
        0
         
      10 SHARED DISPOSITIVE POWER
        3,249,534

     

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
      3,249,534  
         
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
         
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
      100%(2)  
         
    14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
      IN  

     

     

    (1) Mr. Thomson disclaims beneficial ownership of the Common Shares as described in Item 5. 

    (2) This percentage is calculated based upon 3,249,534 outstanding Common Shares of the Issuer as of August 15, 2023 as reported in the Issuer’s Proxy Circular which is attached as Exhibit (a)(2)(i) to the Schedule 13E-3 filed with the SEC on August 17, 2023.

     

    4

     

     

    CUSIP No. 53272L202

     

    1 NAMES OF REPORTING PERSONS  
      Eugene Siklos(1)  
         
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨
        (b) ¨
         
    3 SEC USE ONLY  
         
    4 SOURCE OF FUNDS (SEE INSTRUCTIONS)  
      OO  
         
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) ¨
         
    6 CITIZENSHIP OR PLACE OF ORGANIZATION  
      Canada  

     

      7 SOLE VOTING POWER
        0
         
    NUMBER OF SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH
    8 SHARED VOTING POWER
      3,249,534
       
    9 SOLE DISPOSITIVE POWER
        0
         
      10 SHARED DISPOSITIVE POWER
        3,249,534

     

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
      3,249,534  
         
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
         
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
      100%(2)  
         
    14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
      IN  

     

     

    (1) Mr. Siklos disclaims beneficial ownership of the Common Shares as described in Item 5.

    (2) This percentage is calculated based upon 3,249,534 outstanding Common Shares of the Issuer as of August 15, 2023 as reported in the Issuer’s Proxy Circular which is attached as Exhibit (a)(2)(i) to the Schedule 13E-3 filed with the SEC on August 17, 2023.

     

    5

     

     

    Explanatory Note

     

    This Amendment No. 4 to Schedule 13D (this “Amendment No. 4”) amends and supplements the statement on Schedule 13D filed with the United States Securities and Exchange Commission (the “SEC”) on November 9, 2020 (as amended and supplemented prior to the date hereof, the “Original Schedule 13D” and as amended by this Amendment No. 4, the “Schedule 13D”) and is being filed by Structured Alpha LP (“SALP”), Thomvest Asset Management Ltd. (“Thomvest”), Mr. Peter J. Thomson and Mr. Eugene Siklos (collectively, the “Reporting Persons”) with respect to the beneficial ownership of common shares, no par value (the “Common Shares”), of Liminal Biosciences Inc. (the “Issuer”).

     

    This Amendment No. 4 is being filed in connection with the completion on September 26, 2023 (the “Closing Date”) of the previously announced plan of arrangement under the provisions of the Canada Business Corporations Act (the “Arrangement”) involving the Issuer and SALP.

     

    Information and defined terms reported in the Original Schedule 13D remain in effect except to the extent that it is amended or superseded by information or defined terms contained in this Amendment No. 4.

     

    Item 4. Purpose of Transaction.

     

    Item 4 of the Original Schedule 13D is hereby amended and restated as follows:

     

    On the Closing Date, the Issuer and SALP announced that the Arrangement was completed. Pursuant to the Arrangement, SALP acquired all of the issued and outstanding Common Shares of the Issuer not previously owned by SALP or its affiliates and associates at a price of US$8.50 per Common Share, payable in cash. As a result of the Arrangement, SALP now owns 100% of the issued and outstanding Common Shares of the Issuer and the Issuer is a wholly-owned subsidiary of SALP.

     

    On September 26, 2023, the Issuer issued a press release (“Press Release”) announcing the completion of the Arrangement, which is filed as Exhibit 99.12 hereto and is incorporated by reference into this Item 4.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5(a)-(c) of the Original Schedule 13D is hereby amended and restated as follows:

     

    (a)-(b) The aggregate number and percentage of Common Shares held by the Reporting Persons to which this Schedule 13D relates is 3,249,534 shares (including Common Shares issuable upon the exercise of Warrants (as defined in Item 3 of the Original Schedule 13D)), constituting 100% of the Issuer’s currently outstanding Common Shares. This percentage is calculated based upon 3,249,534 outstanding Common Shares of the Issuer as of August 15, 2023 as reported in the Issuer’s Proxy Circular which is attached as Exhibit (a)(2)(i) to the Schedule 13E-3 filed with the SEC on August 17, 2023. In addition, SALP owns 394,737 Common Shares issuable to SALP upon exercise of the Warrants (as defined in Item 3 of the Original Schedule 13D).

     

    (i) SALP

     

    (a)SALP may be deemed the beneficial owner of 3,249,534 Common Shares, constituting a percentage of 100%.
    (b)Sole voting power to vote or direct vote: 3,249,534 Common Shares
      Shared voting power to vote or direct vote: 0 Common Shares
      Sole power to dispose or direct the disposition: 3,249,534 Common Shares
      Shared power to dispose or direct the disposition: 0 Common Shares

     

    (ii) Thomvest

     

    (a)Thomvest may be deemed the beneficial owner of 3,249,534 Common Shares, constituting a percentage of 100%.
    (b)Sole voting power to vote or direct vote: 0 Common Shares
      Shared voting power to vote or direct vote: 3,249,534 Common Shares
      Sole power to dispose or direct the disposition: 0 Shares
      Shared power to dispose or direct the disposition: 3,249,534 Common Shares

     

    (iii) Mr. Thomson

     

    (a)Mr. Thomson may be deemed the beneficial owner of 3,249,534 Common Shares, constituting a percentage of 100%.
    (b)Sole voting power to vote or direct vote: 0 Common Shares
      Shared voting power to vote or direct vote: 3,249,534 Common Shares
      Sole power to dispose or direct the disposition: 0 Common Shares
      Shared power to dispose or direct the disposition: 3,249,534 Common Shares

     

    (iv) Mr. Siklos

     

    (a)Mr. Siklos may be deemed the beneficial owner of 3,249,534 Common Shares, constituting a percentage of 100%.
    (b)Sole voting power to vote or direct vote: 0 Common Shares
      Shared voting power to vote or direct vote: 3,249,534 Common Shares
      Sole power to dispose or direct the disposition: 0 Common Shares
      Shared power to dispose or direct the disposition: 3,249,534 Common Shares
    (c)Other than the transactions described herein and in the original Schedule 13D, there have been no transactions by the Reporting Persons in the Common Shares during the past 60 days.

     

    6

     

     

    Neither the filing of this Schedule 13D nor any of its contents shall be deemed an admission that either of Mr. Thomson or Mr. Siklos is the beneficial owner of the Common Shares or Warrants referred to herein for purposes of Section 13(d) or Section 13(g) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    The information set forth in Item 4 of this Amendment No. 4 is hereby incorporated by reference into Item 6 of the Original Schedule 13D.

     

    Item 7. Materials to Be Filed as Exhibits.

     

    Item 7 of the Original Schedule 13D is hereby amended and supplemented as follows:

     

    99.12 Press Release, dated September 26, 2023 (incorporated by reference to Exhibit 99.1 of the Issuer’s Form 6-K filed with the SEC on September 26, 2023)

     

    7

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    September 27, 2023 STRUCTURED ALPHA LP, by its general partner, THOMVEST ASSET MANAGEMENT LTD.
       
      By: /s/ Eugene Siklos
        Name: Eugene Siklos
        Title: President
       
      THOMVEST ASSET MANAGEMENT LTD.
       
      By: /s/ Eugene Siklos
        Name: Eugene Siklos
        Title: President
       
      PETER J. THOMSON
       
        /s/ Peter J. Thomson
        Peter J. Thomson
       
      EUGENE SIKLOS
       
        /s/ Eugene Siklos
        Eugene Siklos

     

    8

     

    Get the next $LMNL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMNL

    DatePrice TargetRatingAnalyst
    6/24/2021Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $LMNL
    Leadership Updates

    Live Leadership Updates

    See more
    • Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders

      LAVAL, QC and CAMBRIDGE, England, June 5, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 5, 2023. A total of 2,235,519 common shares were voted, representing 72.02% of the votes attached to the issued and outstanding common shares of Liminal BioSciences. Election of Directors of the CompanyThe six (6) nominees set forth in the Circular were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Name of Nominee For Against  Votes % Votes % Si

      6/5/23 4:05:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results

      CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023Addition of GPR40 agonist discovery program aiming for the development of a novel liver-safe GPR40 agonist for the treatment of type 2 diabetes Closed December 31, 2022 with just over CAD 37 million cash on hand, expecting to provide cash runway into early 2024Net loss from continuing operations of CAD 6.6 million during the quarter ended December 31, 2022 compared to CAD 8.8 million during the fourth quarter of 2021Regained compliance with minimum bid price requirement for continued listing on the Nasdaq Capital MarketCompleted the sale of a non-core real estate asset at

      3/15/23 4:05:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights

      $40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras developmentTermination of legacy CDMO agreement for cash savings of $33.1 millionNet loss from continuing operations of $4.5 million during the quarter ended September 30, 2022 compared to $9.7 million net loss for the same period 2021Current cash runway is anticipated to support our near-term development goals into the fourth quarter of fiscal 2023Possibilities to sell non-core assets to further extend runway into 2024Changes to strengthen executive leadership teamLAVAL, QC and CAMBRIDGE, England, Nov. 9, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today

      11/9/22 4:05:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Liminal BioSciences downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Liminal BioSciences from Buy to Neutral

      6/24/21 7:18:08 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal Biosciences downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Liminal Biosciences from Overweight to Neutral and set a new price target of $4.50 from $22.00 previously

      6/2/21 6:25:42 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright initiated coverage on Liminal BioSciences with a new price target

      HC Wainwright initiated coverage of Liminal BioSciences with a rating of Buy and set a new price target of $11.00

      2/25/21 10:46:46 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    Financials

    Live finance-specific insights

    See more
    • Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023

      LAVAL, QC, and CAMBRIDGE, England, March 13, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter and year ended 2022 financial results after market close on Wednesday March 15, 2023. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday March 16, 2023. To join the conference call without operator assistance, you may register and enter your phone number at https://bit.ly/3FeNJBk to receive an instant automated call back.

      3/13/23 4:05:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022

      LAVAL, QC and CAMBRIDGE, England, Nov. 8, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter 2022 financial results after market close on November 9, 2022. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday November 10, 2022. The telephone numbers to access the conference call are 888-205-6786 and 647-484-0474, using the following passcode: 722285. An audio replay of the call will be available as of Thursday November

      11/8/22 7:00:00 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

      $55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras developmentNet loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the second quarter ended June 30, 2022. Liminal BioSciences will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Wednesday August 10, 2022. The telephone numbers to access the conference call are 888-390-0620 and 416-764-8651. An a

      8/9/22 5:07:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

      LAVAL, QC and CAMBRIDGE, England, Sept. 26, 2023 /PRNewswire/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., was completed earlier today (the "Arrangement"). Pursuant to the Arrangement, SALP acquired all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates (the "Min

      9/26/23 8:00:00 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

      LAVAL, QC and CAMBRIDGE, England, Sept. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price o

      9/19/23 4:22:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

      LAVAL, QC and CAMBRIDGE, England, Sept. 15, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price of US$8.50 per Share, payable in cash (the "Arrangement"). Further

      9/15/23 11:29:00 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Liminal BioSciences Inc. (Amendment)

      SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)

      9/27/23 4:05:14 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Liminal BioSciences Inc. (Amendment)

      SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)

      7/12/23 7:09:48 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Liminal BioSciences Inc. (Amendment)

      SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)

      4/5/23 7:30:30 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Liminal BioSciences Inc.

      15-12G - Liminal BioSciences Inc. (0001351172) (Filer)

      10/6/23 8:30:57 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Liminal BioSciences Inc.

      EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)

      9/27/23 12:15:18 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Liminal BioSciences Inc.

      EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)

      9/27/23 12:15:20 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care